Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal

Jessica A. Fleming; Yakou Dieye; Ousseynou Ba; Boniface Mutombo Wa Mutombo; Ndiouga Diallo; Pape Coumba Faye; Mamadou Ba; Moussa Fafa Cisse; Aissatou Gaye Diallo; Mady Ba; Mary Slack; Noel S. Weiss

doi:10.1097/INF.0b013e318203aaa0

Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal

Jessica A. Fleming, Yakou Dieye, Ousseynou Ba, Boniface Mutombo Wa Mutombo, Ndiouga Diallo, Pape Coumba Faye, Mamadou Ba, Moussa Fafa Cisse, Aissatou Gaye Diallo, Mady Ba, Mary Slack, Noel S. Weiss

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

A total of 24 cases of hospitalized, laboratory-confirmed Haemophilus influenzae type b (Hib) meningitis were identified through a regional pediatric bacterial meningitis surveillance system. Each case was matched by age and residence to 4 neighborhood controls. The adjusted vaccine effectiveness for ≥2 doses was 95.8% (95% confidence interval, 67.9%-99.4%). Hib vaccine appears to be highly effective in preventing Hib meningitis in Senegal.

Original language	English
Pages (from-to)	430-432
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	30
Issue number	5
DOIs	https://doi.org/10.1097/INF.0b013e318203aaa0
Publication status	Published - May 2011

Bibliographical note

Funding Information:
Supported by The Bill and Melinda Gates Foundation.

Funding Information:
With funding from the GAVI Alliance, the Senegal Ministry of Health (MOH) introduced Hib conjugate vaccine into their routine immunization program in July 2005. The case–control study described in this study is part of the Hib Impact Project, a collaborative evaluation of the burden of Hib disease in the country, conducted by the MOH and PATH, an international, nonprofit organization. It includes cases identified through a regional pediatric bacterial meningitis (PBM) surveillance system and provides additional evidence for ongoing support of Hib vaccine by the MOH, when Senegal's GAVI Alliance vaccine donation ends in 2010.

Keywords

bacterial meningitis
Haemophilus influenzae type b
Haemophilus influenzae type b conjugate vaccine
Senegal
vaccine effectiveness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0b013e318203aaa0

Cite this

@article{4447f5c0f58246c38e9c54dc518617dc,

title = "Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal",

abstract = "A total of 24 cases of hospitalized, laboratory-confirmed Haemophilus influenzae type b (Hib) meningitis were identified through a regional pediatric bacterial meningitis surveillance system. Each case was matched by age and residence to 4 neighborhood controls. The adjusted vaccine effectiveness for ≥2 doses was 95.8% (95% confidence interval, 67.9%-99.4%). Hib vaccine appears to be highly effective in preventing Hib meningitis in Senegal.",

keywords = "bacterial meningitis, Haemophilus influenzae type b, Haemophilus influenzae type b conjugate vaccine, Senegal, vaccine effectiveness",

author = "Fleming, {Jessica A.} and Yakou Dieye and Ousseynou Ba and {Mutombo Wa Mutombo}, Boniface and Ndiouga Diallo and Faye, {Pape Coumba} and Mamadou Ba and Cisse, {Moussa Fafa} and Diallo, {Aissatou Gaye} and Mady Ba and Mary Slack and Weiss, {Noel S.}",

note = "Funding Information: Supported by The Bill and Melinda Gates Foundation. Funding Information: With funding from the GAVI Alliance, the Senegal Ministry of Health (MOH) introduced Hib conjugate vaccine into their routine immunization program in July 2005. The case–control study described in this study is part of the Hib Impact Project, a collaborative evaluation of the burden of Hib disease in the country, conducted by the MOH and PATH, an international, nonprofit organization. It includes cases identified through a regional pediatric bacterial meningitis (PBM) surveillance system and provides additional evidence for ongoing support of Hib vaccine by the MOH, when Senegal's GAVI Alliance vaccine donation ends in 2010. ",

year = "2011",

month = may,

doi = "10.1097/INF.0b013e318203aaa0",

language = "English",

volume = "30",

pages = "430--432",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott, Williams & Wilkins",

number = "5",

}

TY - JOUR

T1 - Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal

AU - Fleming, Jessica A.

AU - Dieye, Yakou

AU - Ba, Ousseynou

AU - Mutombo Wa Mutombo, Boniface

AU - Diallo, Ndiouga

AU - Faye, Pape Coumba

AU - Ba, Mamadou

AU - Cisse, Moussa Fafa

AU - Diallo, Aissatou Gaye

AU - Ba, Mady

AU - Slack, Mary

AU - Weiss, Noel S.

N1 - Funding Information: Supported by The Bill and Melinda Gates Foundation. Funding Information: With funding from the GAVI Alliance, the Senegal Ministry of Health (MOH) introduced Hib conjugate vaccine into their routine immunization program in July 2005. The case–control study described in this study is part of the Hib Impact Project, a collaborative evaluation of the burden of Hib disease in the country, conducted by the MOH and PATH, an international, nonprofit organization. It includes cases identified through a regional pediatric bacterial meningitis (PBM) surveillance system and provides additional evidence for ongoing support of Hib vaccine by the MOH, when Senegal's GAVI Alliance vaccine donation ends in 2010.

PY - 2011/5

Y1 - 2011/5

N2 - A total of 24 cases of hospitalized, laboratory-confirmed Haemophilus influenzae type b (Hib) meningitis were identified through a regional pediatric bacterial meningitis surveillance system. Each case was matched by age and residence to 4 neighborhood controls. The adjusted vaccine effectiveness for ≥2 doses was 95.8% (95% confidence interval, 67.9%-99.4%). Hib vaccine appears to be highly effective in preventing Hib meningitis in Senegal.

AB - A total of 24 cases of hospitalized, laboratory-confirmed Haemophilus influenzae type b (Hib) meningitis were identified through a regional pediatric bacterial meningitis surveillance system. Each case was matched by age and residence to 4 neighborhood controls. The adjusted vaccine effectiveness for ≥2 doses was 95.8% (95% confidence interval, 67.9%-99.4%). Hib vaccine appears to be highly effective in preventing Hib meningitis in Senegal.

KW - bacterial meningitis

KW - Haemophilus influenzae type b

KW - Haemophilus influenzae type b conjugate vaccine

KW - Senegal

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=79954826846&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e318203aaa0

DO - 10.1097/INF.0b013e318203aaa0

M3 - Article

AN - SCOPUS:79954826846

SN - 0891-3668

VL - 30

SP - 430

EP - 432

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 5

ER -

Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this